Generic Drugmakers Face An Increasingly Uncertain World: Moody’s
esilverman
The forecast calls for pain. After a recent spate of judicial and regulatory decisions, generic drugmakers face higher legal, regulatory and insurance costs. And ...
Shire Launches Educational Resource for Diabetes
barbara.lempert
Shire Launches Educational Resource for People Living with Diabetes and Their Caregivers HealTogether.com is designed to increase patient awareness of diabetic ...
Lundbeck Reports 2Q Loss
barbara.lempert
New Products up 48%, Lundbeck raises expectations for 2013
Valby, Copenhagen, 7 August 2013 – H. Lundbeck A/S (Lundbeck) reports first half revenue of ...
EpiCept Reports Second Quarter 2013 Operating and Financial Results
barbara.lempert
Special August 6 Stockholder Meeting to Approve Final Conditions to Merger with Immune Pharmaceuticals TARRYTOWN, N.Y., Aug. 1, 2013 /PRNewswire/ — EpiCept Corporation ...
Medicines Co. wraps $240M deal to buy ProFibrix following PhIII success
John Carroll
FierceBiotech News
SIGA Selects Lead Candidate for Dengue Antiviral Program
barbara.lempert
NEW YORK, Aug. 1, 2013 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (Nasdaq:SIGA) today announced that it has selected a lead candidate for its dengue fever antiviral ...
Analysts grow skeptical about Sanofi’s $800M bet on dengue vaccine
Ryan McBride
Sanofi is betting an estimated $ 800 million for research and a new facility to produce an experimental vaccine for dengue–and not all analysts are giving the pharma ...
Hypermarcas leaps ahead in Brazil with surprise profits, sales surge
Tracy Staton
Brazilian drugmaker Hypermarcas shows that market savvy pays, even when an economy hits the skids. Despite an unexpected lag in GDP growth, Hypermarcas posted a surprise ...
Opioid receptor could guide drug R&D on addiction
John Carroll
Investigators from the Florida campus of the Scripps Research Institute have found that a compound that favors a certain biological pathway could provide scientists ...
The FDA OKs 5 blockbusters in slow start to 2013 drug approvals
John Carroll
Few productivity metrics in biopharma measure up to the annual rate of new drug approvals. So now that the FDA has come through with only 13 novel approvals in the first ...
Compugen, Bayer in Potential $500M Deal
barbara.lempert
Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies
Compugen to hold 2nd Quarter Conference Call August ...
FDA Committee to Review COPD Drug
mia.burns
Theravance Announces FDA Advisory Committee to Review ANORO(TM) ELLIPTA(TM) (UMEC/VI) for COPD
SOUTH SAN FRANCISCO, CA — (Marketwired) — 08/01/13 –Theravance, ...